Laekna Pharmaceutical Ningbo Co. Ltd. has synthesized compounds acting as phosphatidylinositol 3-kinase α (PI3Kα) inhibitors reported to be useful for the treatment of cancer.
Wigen Biomedicine Technology (Shanghai) Co. Ltd. has disclosed phosphatidylinositol 3-kinase α (PI3Kα) inhibitors reported to be useful for the treatment of solid cancers and hematological cancers.
Inventisbio Co. Ltd. and Inventisbio LLC have synthesized phosphatidylinositol 3-kinase α (PI3Kα) E542K mutant inhibitors reported to be useful for the treatment of cancer, PIK3CA-related overgrowth spectrum (PROS) and congenital lipomatous overgrowth, vascular malformations, epidermal naevi and skeletal abnormalities (CLOVES syndrome).
Gilead Sciences Inc. has reported new compounds acting as phosphatidylinositol 3-kinase α (PI3Kα) inhibitors reported to be useful for the treatment of cancer.
Shanghai Yingli Pharmaceutical Co. Ltd. has divulged phosphatidylinositol 3-kinase α (PI3Kα) (H1047R mutant) inhibitors reported to be useful for the treatment of cancer.
Ensem Therapeutics Inc. has disclosed phosphatidylinositol 3-kinase α (PI3Kα) inhibitors, particularly PI3Kα mutant inhibitors, reported to be useful for the treatment of cancer.
Relay Therapeutics Inc. has disclosed compounds acting as phosphatidylinositol 3-kinase α (PI3Kα) inhibitors reported to be useful for the treatment of cancer and PIK3CA-related overgrowth spectrum (PROS).
Synnovation Therapeutics Inc. has prepared and tested phosphatidylinositol 3-kinase α (PI3Kα) inhibitors reported to be useful for the treatment of cancer and more.
Ensem Therapeutics Inc. has gained IND clearance from the FDA for ETX-636, a novel allosteric pan-mutant-selective PI3Kα inhibitor and degrader. A first-in-human trial will begin this quarter. The phase I/II study will evaluate ETX-636 administered alone and in combination with fulvestrant in participants with advanced solid tumors, including breast cancer, harboring a PI3Kα mutation.
Shanghai Allist Pharmaceuticals Co. Ltd. has described phosphatidylinositol 3-kinase α (PI3Kα, H1047R mutant) allosteric inhibitors reported to be useful for the treatment of cancer.
